Your browser doesn't support javascript.
loading
The plasma miRNome and venous thromboembolism in high-grade glioma: miRNA Sequencing of a nested case-control cohort.
Erhart, Friedrich; Widhalm, Georg; Kiesel, Barbara; Hackl, Matthias; Diendorfer, Andreas; Preusser, Matthias; Rössler, Karl; Thaler, Johannes; Pabinger, Ingrid; Ay, Cihan; Riedl, Julia.
Affiliation
  • Erhart F; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
  • Widhalm G; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
  • Kiesel B; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
  • Hackl M; TAmiRNA GmbH, Vienna, Austria.
  • Diendorfer A; TAmiRNA GmbH, Vienna, Austria.
  • Preusser M; Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Rössler K; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
  • Thaler J; Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Pabinger I; Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Ay C; Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Riedl J; Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
J Cell Mol Med ; 28(8): e18149, 2024 Apr.
Article in En | MEDLINE | ID: mdl-38613361
ABSTRACT
Patients with high-grade gliomas are at high risk of venous thromboembolism (VTE). MicroRNAs (miRNAs) are small non-coding RNAs with multiple roles in tumour biology, haemostasis and platelet function. Their association with VTE risk in high-grade glioma has not been comprehensively mapped so far. We thus conducted a nested case-control study within 152 patients with WHO grade IV glioma that had been part of a prospective cohort study on VTE risk factors. At inclusion a single blood draw was taken, and patients were thereafter followed for a maximum of 2 years. During that time, 24 patients (16%) developed VTE. Of the other 128 patients, we randomly selected 24 age- and sex-matched controls. After quality control, the final group size was 21 patients with VTE during follow-up and 23 without VTE. Small RNA next-generation sequencing of plasma was performed. We observed that hsa-miR-451a was globally the most abundant miRNA. Notably, 51% of all miRNAs showed a correlation with platelet count. The analysis of miRNAs differentially regulated in VTE patients-with and without platelet adjustment-identified potential VTE biomarker candidates such as has-miR-221-3p. Therewith, we here provide one of the largest and deepest peripheral blood miRNA datasets of high-grade glioma patients so far, in which we identified first VTE biomarker candidates that can serve as the starting point for future research.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: MicroRNAs / Venous Thromboembolism / Glioma Limits: Humans Language: En Journal: J Cell Mol Med Journal subject: BIOLOGIA MOLECULAR Year: 2024 Type: Article Affiliation country: Austria

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: MicroRNAs / Venous Thromboembolism / Glioma Limits: Humans Language: En Journal: J Cell Mol Med Journal subject: BIOLOGIA MOLECULAR Year: 2024 Type: Article Affiliation country: Austria